Cingulate (Cingulate) Scaled Net Operating Assets : 0.72 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Cingulate Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Cingulate's operating assets for the quarter that ended in Mar. 2024 was $4.38 Mil. Cingulate's operating liabilities for the quarter that ended in Mar. 2024 was $1.86 Mil. Cingulate's Total Assets for the quarter that ended in Dec. 2023 was $3.49 Mil. Therefore, Cingulate's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was 0.72.

Cingulate Scaled Net Operating Assets Historical Data

The historical data trend for Cingulate's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cingulate Scaled Net Operating Assets Chart

Cingulate Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

0.43

0.41

0.90

0.19

-0.30

Cingulate Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial												0.36	0.27	0.29	-0.58	0.72

Competitive Comparison of Cingulate's Scaled Net Operating Assets

For the Biotechnology subindustry, Cingulate's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cingulate's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cingulate's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Cingulate's Scaled Net Operating Assets falls into.

Cingulate Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Cingulate's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(3.439	-	6.851)	/	11.405
=	-0.30

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	3.491	-	0.052
=	3.439

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	10.361	-	0.135	-	3.375
=	6.851

Cingulate's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2024 )
=	(Operating Assets (Q: Mar. 2024 )	-	Operating Liabilities (Q: Mar. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(4.381	-	1.855)	/	3.491
=	0.72

where

	Operating Assets		(Q: Mar. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	5.495	-	1.114
=	4.381

	Operating Liabilities		(Q: Mar. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	2.278	-	0.033	-	0.39
=	1.855

Cingulate Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Cingulate's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cingulate (Cingulate) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cingulate Inc (NAS:CING) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

1901 W. 47th Place, Kansas, KS, USA, 66205

Website

https://www.cingulate.com

Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.

Executives

Jennifer L. Callahan	officer: Corporate Controller	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Peter J. Werth	director, 10 percent owner	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Shane J. Schaffer	director, 10 percent owner, officer: Chief Executive Officer	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Craig S. Gilgallon	officer: EVP & General Counsel	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Laurie Myers	officer: EVP & Chief Operating Officer	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Gregg Wm Givens	director	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Scott Applebaum	director	C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
Curtis Medeiros	director	2120 COLORADO AVE., SUITE 230, SANTA MONICA CA 90404
Van Horn Louis G	officer: EVP & Chief Financial Officer	C/O CINGULATE THERAPEUTICS, 1901 W. 47TH PLACE, THIRD FLOOR, KANSAS CITY KS 66205
Patrick Joseph Gallagher	director	275 PLEASANT HILL RD., FLANDERS NJ 07836
Jeffrey X Conroy	director	2372 MORSE AVE, IRVINE CA 92614
Thomas Jeffrey Hargroves	director	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Raul R. Silva	officer: EVP & Chief Science Officer	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Matthew Brams	officer: EVP & Chief Medical Officer	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Fountainhead Shrugged, Llc	10 percent owner	1901 W. 47TH PLACE, #310, KANSAS CITY KS 66205